Can a progesterone patch cause pulmonary embolism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Progesterone-Only Patches Do Not Increase Pulmonary Embolism Risk

Pure progesterone-only contraceptives, including patches, do not significantly increase the risk of pulmonary embolism (PE), with the important exception of depot medroxyprogesterone acetate (DMPA) injections. The thrombotic risk associated with hormonal contraception is primarily driven by the estrogen component, not progesterone alone 1.

Key Evidence on Progestin-Only Contraception and VTE Risk

The most comprehensive guideline evidence shows that progestin-only contraceptives (POPs, implants, levonorgestrel IUDs) demonstrate no excess risk of venous thromboembolism compared to non-users 1. A meta-analysis of progestin-based contraception found an odds ratio of 1.45 (95% CI: 0.92–2.26) for VTE, but this was not statistically significant and varied substantially by drug type 1.

Specifically:

  • Levonorgestrel, norethisterone, and desogestrel at microdoses: No excess VTE risk 1
  • Levonorgestrel IUDs: Very reassuring data with no significant VTE increase 1
  • Progestin-only pills and implants: Generally not associated with elevated VTE or arterial thromboembolism risk 2, 3

The DMPA Exception

DMPA (depot medroxyprogesterone acetate) injections are the notable exception, showing elevated VTE risk in multiple studies 1, 2, 3. This appears related to the high doses and unique pharmacological properties of this specific progestin. A 2025 systematic review confirmed that VTE risk is generally elevated with DMPA use but not with other progestin-only methods 2.

Combined Hormonal Contraceptive Patches: A Different Story

If you're asking about combined estrogen-progestin patches (not progesterone-only), the answer is completely different. Combined contraceptive patches containing both estrogen and progestin do increase thromboembolism risk by a factor of 3 to 4 1. The FDA drug label for progesterone transdermal products used with estrogen explicitly warns of increased PE risk 4.

The WHI study demonstrated that estrogen plus progestin therapy resulted in:

  • 2-fold greater rate of VTE (35 vs 17 per 10,000 women-years) 4
  • PE risk doubled (18 vs 8 per 10,000 women-years) 4
  • Risk highest in the first year and persisted throughout use 4

Clinical Decision Algorithm

For progesterone-only patches:

  • Safe to use without increased PE risk
  • Monitor for standard contraindications

For combined estrogen-progestin patches:

  • Avoid in women with:
    • Personal history of DVT/PE 1
    • Inherited thrombophilia (risk multiplied 5-16 fold) 1
    • Age >40 years 1
    • Obesity 1
    • Smoking 1
    • Recent surgery or immobilization 1
    • Postpartum period 1

Discontinue immediately if PE suspected and switch to non-hormonal or progestin-only alternatives 4.

Critical Pitfalls to Avoid

  1. Don't confuse progestin-only with combined hormonal contraceptives - the thrombotic risk profiles are completely different
  2. DMPA is not representative of all progestin-only methods - it has unique risks not shared by other progestin-only contraceptives
  3. The estrogen component drives thrombotic risk - multiple studies confirm progestin-only pills are not associated with BP elevation or VTE, suggesting estrogen is the culprit 5, 1
  4. Risk is highest in the first year of combined hormonal contraceptive use 1

References

Related Questions

In a 38-year-old woman with persistent dyspnea four months after an acute pulmonary embolism treated with three months of anticoagulation, which test should be ordered next: a 6‑minute walk test, CT pulmonary angiography, ventilation‑perfusion (V/Q) lung scan, or pulmonary angiography?
In a 53-year-old male with ischemic heart disease presenting with acute severe dyspnea, tachypnea, tachycardia, hypoxemia (SpO₂ 88%), impaired renal function (creatinine clearance 27 mL/min) and obesity (BMI 41), suspected pulmonary embolism, which anticoagulant should be administered?
How should I evaluate and manage a patient with shortness of breath and chest pain who may have an acute infection, sepsis, and possible pulmonary embolism?
Is it safe to continue Aygestin (norethindrone) after developing a blood clot, despite a hematologist's assurance that the medication does not cause blood clots?
What estrogen‑free contraceptive options are appropriate for a 19‑year‑old woman with a new left‑leg deep vein thrombosis who is taking apixaban (Eliquis)?
In a 13-year-old male with persistent inflammatory papules and pustules on the face and back despite diligent use of adapalene and 5% benzoyl peroxide, should oral doxycycline, isotretinoin, topical tretinoin, or spironolactone be added?
What should a co-managing ophthalmologist do for a patient being treated for eclampsia?
What outpatient management is recommended after resolution of an acute agitation episode, including labs, medication reconciliation, and follow‑up?
What is the most effective anticonvulsant to add to a patient already taking oxcarbazepine for seizure control?
Can superficial thrombophlebitis of the foot become infected?
What starting dose of lamotrigine (Lamictal) should be used in a patient who is currently taking oxcarbazepine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.